STAT3 and non-small cell lung carcinoma: Because PTPRT is an endogenous inhibitor of STAT3 (Sen et al., 2020), loss-of-function mutations in PTPRT resulted in STAT3 hyperactivation to promote the malignancy of NSCLC (Wang et al., 2021).